Table 3.
Sensitivity analyses results for semaglutide 1 mg versus dulaglutide 1.5 mg based on SUSTAIN 7
| Analysis | Discounted quality-adjusted life expectancy (QALYs) | Discounted direct costs (DKK) | ICER (DKK per QALY gained) | ||||
|---|---|---|---|---|---|---|---|
| Semaglutide 1 mg | Dulaglutide 1.5 mg | Difference | Semaglutide 1 mg | Dulaglutide 1.5 mg | Difference | ||
| Base case | 9.41 | 9.08 | + 0.34 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
| 20-year time horizon | 8.17 | 7.88 | + 0.28 | 295,697 | 306,919 | − 11,222 | Semaglutide dominant |
| 10-year time horizon | 5.48 | 5.28 | + 0.20 | 152,959 | 167,743 | − 14,785 | Semaglutide dominant |
| Statistically significant differences only | 9.40 | 9.08 | + 0.32 | 403,334 | 415,489 | − 12,156 | Semaglutide dominant |
| First treatment intensification at HbA1c ≥ 7.0% and second intensification at HbA1c ≥ 7.5% | 9.16 | 8.88 | + 0.28 | 427,307 | 438,257 | − 10,950 | Semaglutide dominant |
| First treatment intensification at HbA1c ≥ 8.0% and second intensification at HbA1c ≥ 8.5% | 9.59 | 9.24 | + 0.34 | 383,083 | 390,248 | − 7165 | Semaglutide dominant |
| Treatment intensification at 3 years | 9.65 | 9.54 | + 0.11 | 386,173 | 382,932 | + 3242 | 30,408 |
| Treatment intensification at 5 years | 9.72 | 9.60 | + 0.12 | 375,320 | 371,568 | + 3753 | 31,721 |
| GLP-1 receptor agonist treatment continued for patient lifetimes | 9.45 | 9.08 | + 0.37 | 476,223 | 502,717 | − 26,494 | Semaglutide dominant |
| Cost of complications + 25% | 9.41 | 9.08 | + 0.34 | 436,659 | 454,138 | − 17,479 | Semaglutide dominant |
| Cost of complications − 25% | 9.41 | 9.08 | + 0.34 | 367,496 | 376,849 | − 9353 | Semaglutide dominant |
| All costs + 25% | 9.41 | 9.08 | + 0.34 | 499,312 | 516,115 | − 16,803 | Semaglutide dominant |
| All costs − 25% | 9.41 | 9.08 | + 0.34 | 304,842 | 314,872 | − 10,030 | Semaglutide dominant |
| Lee et al. BMI disutility applied | 8.96 | 8.57 | + 0.40 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
| Evans et al. hypoglycemia disutilities applied | 9.30 | 8.94 | + 0.37 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
| Currie et al. hypoglycemia disutilities applied | 9.49 | 9.17 | + 0.32 | 402,073 | 415,489 | − 13,416 | Semaglutide dominant |
BMI body mass index, DKK 2017 Danish kroner, HbA1c glycated hemoglobin, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year